Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Celldex Therapeutics, Inc.

NASDAQ: CLDX · Life Sciences · 3 alerts · CIK 744218

Share price
$28.59Close, Nov 16
Market cap
$2.25B
Shares outstanding
78.55MLatest SEC cover page
Sector
Life Sciences
Industry
In Vitro & In Vivo Diagnostic SubstancesSIC 2835

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Celldex Therapeutics, Inc. filings on SEC EDGAR ↗

4:10 PM ET 10-Q
Financial Results

Celldex Therapeutics Q3 2026 Results: Net Loss of $75.6M, Loss Widens

Celldex Therapeutics reported a net loss of $227.7 million for the first nine months of 2026, driven by increased research and development expenses. The company significantly strengthened its balance sheet through stock issuances, ending the period with $650.3 million in cash, cash equivalents, and marketable securities, which management believes is sufficient to fund operations for at least twelve months.

Key figure
Net loss $75.6M
4:02 PM ET 8-K
Financial Results

Celldex Therapeutics Financial Results

Celldex Therapeutics reported third quarter 2026 financial results and provided a corporate update on its barzolvolimab program. The company highlighted positive Phase 3 topline results in chronic spontaneous urticaria (CSU) and anticipates a BLA submission in 2027.

“Barzolvolimab has significant potential to address enormous populations of high unmet need and shift the treatment paradigm goal from symptom improvement to complete symptom resolution, which for patients means no itch, no hives, no swelling.”

Anthony Marucci, Co-founder, President and Chief Executive Officer

“This quarter we reported best-in-disease results from our two Phase 3 studies in CSU, demonstrating barzolvolimab’s unparalleled ability to deliver complete response to patients—including even in patient populations suffering with severe disease or severe angioedema or with omalizumab refractory disease.”

Anthony Marucci, Co-founder, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.